1-(5-甲氧基-1-苯并呋喃-3-基)丙烷-2-酮 | 56798-52-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 1-(5-甲氧基-1-苯并呋喃-3-基)丙烷-2-酮
• 英文名称: 1-(5-methoxybenzofuran-3-yl)-2-propanone
• 英文别名: 1-(5-methoxybenzofuran-3-yl)propan-2-one；(5-methoxy-benzofuran-3-yl)-propan-2-one；1-(5-methoxy-1-benzofuran-3-yl)acetone；1-(5-Methoxy-1-benzofuran-3-yl)propan-2-one
• CAS: 56798-52-8
• 化学式: C₁₂H₁₂O₃
• 分子量: 204.225
• InChiKey: SITQCVWRMFSBMQ-UHFFFAOYSA-N

物化性质

• 熔点：
  46-47 °C
• 沸点：
  313.2±27.0 °C(Predicted)
• 密度：
  1.155±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(5-甲氧基-1-苯并呋喃-3-基)丙烷-2-酮 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以98%的产率得到1-(5-甲氧基苯并呋喃-3-基)-2-丙醇
  参考文献：
  名称：

  Benzofuran bioisosteres of hallucinogenic tryptamines

  摘要：

  The benzofuran analogues of the hallucinogens 5-methoxy-NN-dimethyltryptamine and 5-methoxy-alpha-methyl-tryptamine were synthesized and evaluated for affinity at the serotonin 5-HT2 and 5-HT1A receptors in rat brain homogenate, labeled with [I-125]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ([I-125]DOI) and [H-3]-8-hydroxy-2-(N,N-di-n-propylamino)tetralin ([H-3]-8-OH-DPAT), respectively. At the 5-HT2 receptor, the benzofurans had slightly decreased affinities, approximately one-third and one-sixth those of the indoles, for the primary amines and the tertiary amines, respectively. The benzofurans also had lower affinity at the 5-HTA1A receptor, but decreased only about 20-30% from that of the indole isosteres. Thus, the 5-HT1A receptor is less discriminating with respect to preference for an indole versus a benzofuran, although all of the compounds did have higher affinities for the 5-HT2 receptor than for the 5-HT1A receptor. It is suggested that benzofurans may be useful in the design of serotonin receptor ligands.

  DOI：

  10.1021/jm00089a017
• 作为产物：
  描述：

  2-diazo-1-(2,5-dimethoxyphenyl)ethanone 在 溶剂黄146 作用下， 以 xylene 为溶剂， 反应 72.5h， 生成 1-(5-甲氧基-1-苯并呋喃-3-基)丙烷-2-酮
  参考文献：
  名称：

  Benzofuran bioisosteres of hallucinogenic tryptamines

  摘要：

  The benzofuran analogues of the hallucinogens 5-methoxy-NN-dimethyltryptamine and 5-methoxy-alpha-methyl-tryptamine were synthesized and evaluated for affinity at the serotonin 5-HT2 and 5-HT1A receptors in rat brain homogenate, labeled with [I-125]-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ([I-125]DOI) and [H-3]-8-hydroxy-2-(N,N-di-n-propylamino)tetralin ([H-3]-8-OH-DPAT), respectively. At the 5-HT2 receptor, the benzofurans had slightly decreased affinities, approximately one-third and one-sixth those of the indoles, for the primary amines and the tertiary amines, respectively. The benzofurans also had lower affinity at the 5-HTA1A receptor, but decreased only about 20-30% from that of the indole isosteres. Thus, the 5-HT1A receptor is less discriminating with respect to preference for an indole versus a benzofuran, although all of the compounds did have higher affinities for the 5-HT2 receptor than for the 5-HT1A receptor. It is suggested that benzofurans may be useful in the design of serotonin receptor ligands.

  DOI：

  10.1021/jm00089a017

文献信息

• [EN] OPIOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR OPIOÏDE
  申请人：UNIV COLUMBIA

  公开号：WO2016086158A1

  公开（公告）日：2016-06-02

  The present invention provides a compound having the structure wherein A is a ring structure, with or without substitution; X1 is C or N; X2 is N, 0, or S; Y1 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 2 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y3 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 4 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y5 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); a and P are each present or absent and when present each is a bond.

  本发明提供了一种具有结构的化合物，其中A是一个环结构，带有或不带有取代基；X1是C或N；X2是N、O或S；Y1是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；Y2是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；Y3是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；Y4是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；Y5是H、-(烷基)、-(烯烃基)、-(炔烃基)、-(环烷基)、(卤代烷基)、-(烷基)-O-(烷基)或-(烷基)-(环烷基)；a和P分别存在或不存在，当存在时，每个都是一个键。
• BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE
  申请人：Venkatesan Aranapakam Mudumbai

  公开号：US20090054454A1

  公开（公告）日：2009-02-26

  Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.

  本专利揭示了苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物以及含有这些化合物的组合物。还揭示了使用苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物以及含有这种组合物在治疗和/或预防与5-羟色胺相关的疾病，如抑郁症和焦虑症的方法。此外，还揭示了制备苯并呋喃基和苯并噻吩基哌嗪喹啉衍生物的方法。
• Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use
  申请人：Venkatesan Mudumbai Aranapakam

  公开号：US20050004162A1

  公开（公告）日：2005-01-06

  3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.

  3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚衍生物已被披露。还披露了使用这些衍生物以及含有这些衍生物的组合物在预防和/或治疗血清素紊乱，如抑郁症和焦虑症方面的方法。此外，还披露了制备3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚衍生物的方法。
• Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
  申请人：Venkatesan Mudumbai Aranapakam

  公开号：US20050059673A1

  公开（公告）日：2005-03-17

  Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed.

  本发明涉及苯并呋喃基-和苯并噻吩基-哌嗪基喹啉衍生物及含有该类化合物的组合物。本发明还涉及使用苯并呋喃基-和苯并噻吩基-哌嗪基喹啉衍生物及含有该类组合物治疗和/或预防与血清素相关的疾病，例如抑郁和焦虑。此外，还公开了制备苯并呋喃基-和苯并噻吩基-哌嗪基喹啉衍生物的方法。
• PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE
  申请人：Venkatesan Mudumbai Aranapakam

  公开号：US20070225319A1

  公开（公告）日：2007-09-27

  3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.

  本发明揭示了3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢-吡啶-4-基)-1H-吲哚衍生物。本发明还揭示了使用这些衍生物和含有这些衍生物的组合物在预防和/或治疗血清素紊乱，如抑郁症和焦虑症方面的方法。此外，本发明还揭示了制备3-哌啶基-1H-吲哚和3-(1,2,3,6-四氢-吡啶-4-基)-1H-吲哚衍生物的过程。